Category Archives: Parkinson’s Treatment

Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death All mentions of NLY01 have been corrected. The corrected release reads: NEURALY ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF NLY01 FOR PATIENTS WITH PARKINSONS DISEASE Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinsons disease Continue reading →

With Parkinsons disease, a progressive nervous system disorder that affects movement, some days you need a little nudge to keep going. Continue reading →

By Dan Hurley March 5, 2020 The Science Explained Article In Brief A unique molecular structureevident in induced pluripotent stem cells taken from people with young-onset Parkinson's diseasesuggests that the defects may be present throughout patients' lives, and that they could therefore be used as diagnostic markers. Induced pluripotent stem cells (iPSCs) taken from patients with young-onset Parkinson's disease (YOPD) and grown into dopamine-producing neurons displayed a molecular signature that was corrected in vitro, as well as in the mice striatum, by a drug already approved by the US Food and Drug Administration (FDA), a study published in the January 27 online edition of Nature Medicine found Continue reading →

Company Will Present at Cowen Healthcare Conference Today NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, provided an update today on the clinical advancement of its gene therapy program PR001 for patients with Parkinsons disease with GBA1 mutations (PD-GBA). Enrollment in the PR001 Phase 1/2 PROPEL clinical trial is progressing, patient dosing continues, and the Company is on track to report interim data on a subset of patients in the second half of 2020 Continue reading →

Support groups bring together people who are going through similar experiences. For many, a health-related support group can fill the gap between medical treatment and the need for emotional support Continue reading →

on March 4, 2020 at 10:54 am THOMAS FASULO OrthoSport Hawaii Medical Gym director In 2009, Dr. Michael Turner started Ortho-Sport Hawaii as an outgrowth of his own passion for leading an active, healthy lifestyle Continue reading →

Lundbeck hopes to find a validated method to diagnose Parkinson's disease. The method is based on a biomarker and can potentially lead to earlier diagnosis of patients Continue reading →

Xconomy National Biogen is opening up its checkbook again to get its hands on innovative approaches to some brain disorders that have proven especially recalcitrant to new types of treatment. Continue reading →

Protocol amendment being implemented for ongoing RESTORE-1 trial of VY-AADC (NBIb-1817) for Parkinsons disease; plan to initiate RESTORE-2 trial in 2H 2020 Update on VY-HTT01 for Huntingtons disease preclinical program expected in 2Q 2020 Strong financial position with ~$282M of cash at the end of 2019 and expected runway into mid-2022 CAMBRIDGE, Mass., March 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its fourth quarter and full year 2019 financial results, program progress and corporate updates. In 2019, we took important steps toward our vision of establishing Voyager as the leader in neurological gene therapy, including forming our strategic collaboration with Neurocrine Biosciences, expanding our partnership with AbbVie, and further progressing our wholly-owned and partnered programs, said Andre Turenne, President and CEO of Voyager. Continue reading →

The Michael J. Fox Foundation for Parkinsons Research (MJFF) has unveiled the redesign of Fox Trial Finder the Foundations online tool to match patients and families to Parkinsons clinical studies that need them. Continue reading →